Citigroup has agreed to pay $425 million to resolve civil charges that it tried to manipulate interest rate benchmarks.
In announcing the settlement on Wednesday, the Commodities Futures Trading Commission said Citigroup affiliates also made false reports in connection with ISDAFIX benchmark rates and dollar Libor rates during the financial crisis to protect its reputation.
The CFTC accused Citigroup of trying to manipulate the benchmarks by certain traders putting in false data to benefit their own trading positions. The various actions occurred between 2007 and 2012.
With the Citigroup settlement, the CFTC said it has imposedmore than $5 billion in penalties in 17 actions against banksand brokers for manipulating benchmarks for interest rates andforeign exchange. The settlement is the latest in a series of ongoing international probes of global banks.
Citi’s settlement sum is sizeable compared to other recent CFTC enforcement actions, but the bank has faced at least one larger regulatory settlement. In 2014, Citi agreed to pay the U.S. Justice Department $7 billion to resolve claims it misled investors about the quality of mortgage-backed securities.
The benchmarks included the US dollar ISDAFIX for fixedinterest rate swaps, the Yen Libor and the Euroyen Tibor.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Athletes File New Objections to NCAA’s $2.8 Billion Settlement Proposal
May 15, 2025 by
CPI
TikTok Charged by EU Over Alleged Breach of Digital Services Act
May 15, 2025 by
CPI
House Budget Bill’s Moratorium on State AI Laws Could Undo A Range of Tech Regs, Critics Say
May 14, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas